In Vitro Characterization of a Simian Immunodeficiency Virus-Human Immunodeficiency Virus (HIV) Chimera Expressing HIV Type 1 Reverse Transcriptase To Study Antiviral Resistance in Pigtail Macaques
Open Access
- 15 December 2004
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (24) , 13553-13561
- https://doi.org/10.1128/jvi.78.24.13553-13561.2004
Abstract
Antiviral resistance is a significant obstacle in the treatment of human immunodeficiency virus type 1 (HIV-1)-infected individuals. Because nonnucleoside reverse transcriptase inhibitors (NNRTIs) specifically target HIV-1 reverse transcriptase (RT) and do not effectively inhibit simian immunodeficiency virus (SIV) RT, the development of animal models to study the evolution of antiviral resistance has been problematic. To facilitate in vivo studies of NNRTI resistance, we examined whether a SIV that causes immunopathogenesis in pigtail macaques could be made sensitive to NNRTIs. Two simian-human immunodeficiency viruses (SHIVs) were derived from the genetic background of SIVmne: SIV-RT-YY contains RT substitutions intended to confer NNRTI susceptibility (V181Y and L188Y), and RT-SHIVmne contains the entire HIV-1 RT coding region. Both mutant viruses grew to high titers in vitro but had reduced fitness relative to wild-type SIVmne. Although the HIV-1 RT was properly processed into p66 and p51 subunits in RT-SHIVmne particles, the RT-SHIVmne virions had lower levels of RT per viral genomic RNA than HIV-1. Correspondingly, there was decreased RT activity in RT-SHIVmne and SIV-RT-YY particles. HIV-1 and RT-SHIVmne were similarly susceptible to the NNRTIs efavirenz, nevirapine, and UC781. However, SIV-RT-YY was less sensitive to NNRTIs than HIV-1 or RT-SHIVmne. Classical NNRTI resis tance mutations were selected in RT-SHIVmne after in vitro drug treatment and were monitored in a sensitive allele-specific real-time RT-PCR assay. Collectively, these results indicate that RT-SHIVmne may be a useful model in macaques for the preclinical evaluation of NNRTIs and for studies of the development of drug resistance in vivo.Keywords
This publication has 66 references indexed in Scilit:
- HIV therapy in 2003AIDS, 2003
- Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus ReplicationJournal of Virology, 2003
- Replication of Phenotypically Mixed Human Immunodeficiency Virus Type 1 Virions Containing Catalytically Active and Catalytically Inactive Reverse TranscriptaseJournal of Virology, 2001
- Anin VivoModel for HIV Resistance DevelopmentAIDS Research and Human Retroviruses, 2001
- Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance 1 1Edited by J. KarnJournal of Molecular Biology, 1998
- Crystal Structures of 8-Cl and 9-Cl TIBO Complexed with Wild-type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-resistant MutantJournal of Molecular Biology, 1996
- Sensitivity/Resistance Profile of a Simian Immunodeficiency Virus Containing the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1 (HIV-1) Toward the HIV-1-Specific Non-nucleoside Reverse Transcriptase InhibitorsBiochemical and Biophysical Research Communications, 1995
- Infectivity of titered doses of simian immunodeficiency virus clone E11S inoculated intravenously into rhesus macaques (Macaca mulatta)Journal of Medical Primatology, 1994
- Generation and characterization of murine monoclonal antibodies reactive against N‐terminal and other regions of HIV‐1 reverse transcriptaseJournal of Medical Virology, 1993
- HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domainNature, 1990